Champions’ CDX platform supports subcutaneous, orthotopic, and disseminated tumor models, allowing researchers to select the study format that best fits their program. For immune relevant applications, models can also be run in humanized systems to evaluate immune cell dynamics and immunotherapy strategies. This flexibility ensures that CDX studies are not one size fits all but instead tailored to the scientific question being asked.
Every CDX model undergoes a rigorous validation process. Champions is continuously expanding and refining its portfolio, with dozens of models in validation at any given time. Models that do not meet strict criteria, such as consistent growth and reproducible behavior, are terminated to maintain quality. Growth curves are presented using industry standard practices, beginning at randomization rather than implant day, and outliers are removed to produce representative, client ready data. These practices ensure that every study benefits from reliable, transparent results that align with the highest industry expectations.
The value of CDX studies extends beyond efficacy readouts. With Lumin Bioinformatics, Champions integrates pharmacology results from CDX models with genomic, transcriptomic, and proteomic data. This enables deeper insights into mechanisms of action, biomarker discovery, and translational relevance. By connecting CDX outcomes with broader datasets, Champions ensures that early in vivo results are not isolated, but part of a larger continuum of discovery and development.
Champions also provides formalin fixed paraffin embedded (FFPE) blocks and tissue microarrays (TMAs) from select CDX models. These resources allow researchers to evaluate target expression patterns across tumors, supporting target validation and biomarker development. While most competitors offer limited access to these materials, Champions is proactively expanding availability, giving clients another tool to strengthen study design.
